Advancing Clinical Trial Outcome Prediction with Domain-Specific Large Language Models
Read the original on arXiv AI →The Flow has not summarised this story yet — read it at arXiv AI.
The Flow has not summarised this story yet — read it at arXiv AI.
arXiv:2610.15029v1 Announce Type: cross Abstract: Automated disease classification from patient-reported symptoms requires balancing the speed of lightweight discriminative models against the context...
The paper presents a method for detecting spin in clinical trials by automatically identifying outcome switching using large language models (LLMs). The authors trained on 300 pairs of outcomes labeled for semantic similarity, then evaluated baseline text similarity models and open-source LLMs, applying prompt engineering, token‑probability classification, and majority voting. On a test set of 2,496 examples, the LLM‑based approach achieved an F1 score of 0.78 and accuracy of 0.90, surpassing baseline models but falling short of fine‑tuned BERT, and also produced natural‑language explanations that were manually evaluated for quality.
arXiv:2605.20292v2 Announce Type: replace Abstract: Numerical time-series models effectively process irregular electronic health record (EHR) trajectories, but do not expose which temporal patterns s...
The paper evaluates whether a 9‑billion parameter decision foundation model, Clef‑Flash, is necessary for symptom‑to‑disease classification. Fine‑tuning the model on the 24‑class Symptom2Disease benchmark yields 95.42% accuracy, but simple TF‑IDF linear classifiers achieve higher accuracy (98.75%) with far faster inference. Ablation studies show that predictions can hinge on single descriptive clauses, indicating that the benchmark may not fully capture the model’s capabilities.
arXiv:2608.03854v4 Announce Type: replace Abstract: Quantized large language models can run on consumer hardware, which motivates interest in on-premises processing of sensitive data. The reliability...
arXiv:2604. 26498v3 Announce Type: replace Abstract: The rapid growth of molecular foundation models and large language models (LLMs) has encouraged a scale centred view of AI in drug discovery, in which larger pretrained models are expected to supersede compact cheminformatics models.